Consonance Capital Management LP Savara Inc Transaction History

Consonance Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$0.71 - $4.91 $1.11 Million - $7.7 Million	-1,568,002 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$2.37 - $11.7 $3.62 Million - $17.9 Million	-1,525,688 Reduced 49.32%	1,568,002 $3.72 Million
Q3 2018 Nov 14, 2018	BUY	$10.49 - $12.87 $4.01 Million - $4.92 Million	382,500 Added 14.11%	3,093,690 $34.5 Million
Q1 2018 May 15, 2018	SELL	$8.99 - $14.95 $402,949 - $670,088	-44,822 Reduced 1.63%	2,711,190 $24.9 Million
Q4 2017 Feb 14, 2018	BUY	$8.26 - $16.76 $22.8 Million - $46.2 Million	2,756,012	2,756,012 $40.9 Million

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.